Drug Trial Radar · NCT07234058
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Apr 2, 2026
Primary completion
May 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, phase IIR, double non-comparative arm trial, with an initial safety run for the anti-LAG3 arm. Approximately 40 sites will participate in the study and will enroll 126 patients with treatment-naive, unresectable malignant PM. Treatment will be administered in 21-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent or for 2 years immunotherapy maximum. Once the patient discontinues study treatment, the treatment period will end and the patient will enter the follow-up period. No cross-over is allowed between arms.
Conditions
- Pleural Mesotheliomas
Interventions
CemiplimabDrug
350mg every 3 weeks for up to 24 months.
FianlimabDrug
1600mg every 3 weeks for up to 24 months.
Pemetrexed (Alimta)Drug
500 mg/m² every 3 weeks for 6 cycles.
CisplatinDrug
75 mg/m² every 3 weeks for 6 cycles.
Carboplatin (AUC 5)Drug
AUC 5 (recommended maximum dose of 800 mg) every 3 weeks for 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the activity of the combination of double immunotherapy anti-LAG3+ anti-PD-1 and pemetrexed+platinum chemotherapyTime frame: 6 months after randomisation.
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Aix-Pertuis - CHI
Aix-en-Provence, France · Not yet recruiting
Amiens - CHU
Amiens, France · Not yet recruiting
Angers - CHU
Angers, France · Not yet recruiting
Avignon - CH
Avignon, France · Not yet recruiting
Besançon - CHU
Besançon, France · Not yet recruiting
Bordeaux - Institut Bergonié
Bordeaux, France · Not yet recruiting
Boulogne - APHP Ambroise Paré
Boulogne-Billancourt, France · Recruiting
Caen - CHU
Caen, France · Not yet recruiting
Clermont-Ferrand - Centre Jean Perrin
Clermont-Ferrand, France · Not yet recruiting
Clermont-Ferrand - CHU
Clermont-Ferrand, France · Not yet recruiting
Créteil - CHI
Créteil, France · Not yet recruiting
Dijon - Centre Georges-François Leclerc
Dijon, France · Not yet recruiting
Grenoble - CHU
Grenoble, France · Not yet recruiting
La Roche-Sur-Yon - CHD Vendée
La Roche-sur-Yon, France · Not yet recruiting
Le Mans - CHG
Le Mans, France · Not yet recruiting
Lille - CHU
Lille, France · Recruiting
Marseille - APHM Nord
Marseille, France · Not yet recruiting
Marseille - Hôpital Européen
Marseille, France · Not yet recruiting
Montpellier - CHU
Montpellier, France · Not yet recruiting
Mulhouse - GHRMSA
Mulhouse, France · Not yet recruiting
Nantes - Hôpital Laennec
Nantes, France · Recruiting
Paris - APHP Bichat
Paris, France · Recruiting
Paris - APHP Cochin
Paris, France · Not yet recruiting
Bordeaux - CHU
Pessac, France · Not yet recruiting
Lyon - HCL
Pierre-Bénite, France · Not yet recruiting
Reims - Institut Godinot
Reims, France · Recruiting
Rennes - CHU
Rennes, France · Not yet recruiting
Nantes - Institut de Cancérologie de l'Ouest
Saint-Herblain, France · Not yet recruiting
Saint-Nazaire - Clinique Mutualiste de l'Estuaire
Saint-Nazaire, France · Not yet recruiting
Strasbourg - Nouvel Hôpital Civil
Strasbourg, France · Recruiting
Toulon - CHI
Toulon, France · Recruiting
Toulon - Sainte Anne HIA
Toulon, France · Not yet recruiting
Toulouse - CHU
Toulouse, France · Recruiting
Tours - CHU
Tours, France · Recruiting
Vandoeuvre-lès-Nancy - Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France · Not yet recruiting
Villefranche sur Saône - CH
Villefranche-sur-Saône, France · Not yet recruiting
Villejuif - Gustave Roussy
Villejuif, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.